The Future of Cardiovascular Diagnostics41

The Future of Cardiovascular Diagnostics41 - DATAMONITOR360...

Info iconThis preview shows pages 1–3. Sign up to view the full content.

View Full Document Right Arrow Icon
DATAMONITOR 360 The Future of Cardiovascular Diagnostics Extracted on: 20 Apr 2011 Reference Code: BI00021-008 Publication Date: 02 Mar 2010 Publisher: Datamonitor © Datamonitor This content is a licensed product, no part of this publication shall be reproduced, sold, modified or stored in a retrieval system or transmitted in any form by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of Datamonitor. The information in this document has been extracted from published research by a registered user of the Datamonitor360 platform. Datamonitor shall not be responsible for any loss of original context and for any changes made to information following its extraction. All information was current at the time of extraction although the original content may have been subsequently updated. Please refer back to the website to view the most recent content and the original source of the information. To the maximum extent permitted by applicable law we exclude all representations, warranties and conditions relating to the facts of all publications. At time of publication no guarantee of accuracy or suitability, whether express or implied, shall attach to this publication (including, without limitation, any warranties implied by law of satisfactory quality, fitness for purpose and/or the use of reasonable care and skill). Please note that the findings, conclusions and recommendations delivered will be based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such Datamonitor can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect. © Datamonitor This report is a licensed product and shall not be reproduced without prior written permission from Datamonitor. Page 1
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
The Future of Cardiovascular Diagnostics Summary The IVD market was estimated to be worth $35bn in 2008 (excluding sales of blood glucose self testing) and is growing at around 3% per annum. Over half of sales were derived from clinical chemistry and immunoassay products however, the PoC market is small but ever increasingly important. Cardiovascular IVDs accounted for around 25% of immunoassay test revenues and PoC sales. The market is dominated by large cap companies including: Abbott Diagnostics, Beckman Coulter Inc., Becton Dickinson and Company (BD), bioMérieux, Johnson & Johnson (Ortho Clinical Diagnostics), Inverness Medical Innovations, Roche Diagnostics, and Siemens Healthcare. The market continues to be driven by advances in new biosensor technologies for use in PoC diagnostics and the identification of novel CV biomarkers (CGEN-114, galectin-3, KLP-6, GDF-15) is ripe for commercialization. The diagnostic imaging market (excluding services) was estimated to be worth around $42bn in
Background image of page 2
Image of page 3
This is the end of the preview. Sign up to access the rest of the document.

This note was uploaded on 08/30/2011 for the course FIN 101 taught by Professor Ands during the Spring '11 term at Bloomsburg.

Page1 / 25

The Future of Cardiovascular Diagnostics41 - DATAMONITOR360...

This preview shows document pages 1 - 3. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online